Skip to main content
Premium Trial:

Request an Annual Quote

Acadia Pharmaceuticals Hires Chief Executive

Premium

SAN DIEGO, Calif.--Acadia Pharmaceuticals here, a biotech company engaged in development and use of high-throughput screening technologies for drug discovery, announced the appointment of Leonard Bormann to the position of CEO. Bormann left the post of vice-president of business development at Allergan, where he worked for 14 years.

Mark Brann, Acadia's current CEO who will continue in his roles as chief scientific officer and president, said Bormann's appointment is key for Acadia. "As a lead discovery company, we need this kind of comprehensive expertise," he said.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.